Select Medical (SEM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
Meeting called to order at 11:00 A.M. Eastern Time as a virtual audio webcast to facilitate stockholder participation and voting.
Proxy statement and meeting notice were mailed to stockholders beginning May 22, 2026, with May 11, 2026, as the record date.
Quorum established with more than half of outstanding shares present or represented by proxy.
Shareholder proposals
Three proposals presented: approval of a merger agreement, a non-binding advisory vote on executive compensation related to the merger, and a potential adjournment proposal.
Merger proposal involves the company becoming a wholly-owned subsidiary of Stallion Intermediate Corporation.
Compensation proposal concerns arrangements for named executive officers in connection with the merger.
Adjournment proposal was not put to a vote as the Board deemed it unnecessary.
Overview of voting outcomes
Merger proposal approved by both a majority of all shares and a majority of unaffiliated stockholder shares voting.
Compensation proposal approved by a majority of shares present or represented by proxy.
Official vote count to be reported on Form 8-K within four business days.
Latest events from Select Medical
- Special meeting to vote on $16.50/share cash merger, with board and committee unanimous support.SEM
Proxy filing - Special Committee recommends approval of a $16.50/share going-private merger, offering an 18% premium.SEM
Proxy filing - Revenue up 5%, but net income and EBITDA fell; merger expected mid-2026, guidance maintained.SEM
Q1 2026 - Independent directors back $16.50/share going-private merger, with appraisal rights and executive pay vote.SEM
Proxy filing - Board seeks annual director elections, 25% special meeting threshold, and strong governance.SEM
Proxy Filing - Key votes include board structure changes, executive pay, and special meeting rights.SEM
Proxy Filing - Q3 2025 revenue up 7.2%, EPS up 21%, margins pressured, 2025 outlook reaffirmed.SEM
Q3 2025 - Q2 revenue up 5.1% to $1.76B; Concentra IPO raised $528.8M, reducing debt by $1.9B.SEM
Q2 2024 - Revenue, net income, and liquidity improved, with Concentra IPO and debt reduction as key highlights.SEM
Q3 2024